Loteprednol etabonate. Ocular antiinflammatory, soft corticosteroid

Drugs of the Future

Volumn 22, Issue 10, 1997, Pages 1086-1090

  Graul, A ^a   Martin, L ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIGOXIN; LOTEPREDNOL ETABONATE; OCULAR ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0031437641     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.10.425579     Document Type: Review

References (38)

1. Bodor, N.S. (Otsuka Pharm. Co., Ltd.). Steroids with antiinflammatory activity. BE 0889563.
2. Druzgala, P., Hochhaus, G., Bodor, N. Soft drugs - 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. J Steroid Biochem Mol Biol 1991, 38: 149-54.
3. Bodor, N. The application of soft drug approaches to the design of safer corticosteroids. In: Topical Corticosteroids Therapy: A Novel Approach to Safer Drugs, E. Christophers et al. (Eds.), Raven Press, Ltd., New York, 1988, 13-25.
4. Leibowitz, H.M., Kupferman, A., Ryan, W.J., Reaves, T.A., Howes, J. Corneal anti-inflammatory efficacy of loteprednol etabonate: A new steroidal "soft drug". Invest Ophthalmol Visual Sci 1991, 32(4): Abst 346.
5. Bodor, N., Murakami, T., Wu, W.-M. Soft drugs 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats - For safer treatment of gastrointestinal inflammation. Pharm Res 1995, 12: 869-74.
6. Druzgala, P.D., Wu, W.M., Winwood, D., Howes, J.F., Reaves, T.A. Ocular absorption and distribution of loteprednol etabonate: A "soft" steroid. Invest Ophthalmol Visual Sci 1991, 32(4): Abst 347.
7. Howes, J.F., Baru, H., Vered, M., Neumann, R. Loteprednol etabonate: Comparison with other steroids in two models of intraocular inflammation. J Ocular Pharmacol 1994, 10: 289-93.
8. Wu, W.-M., Muakami, T., Bodor, N. GI application of a soft corticosteroid, loteprednol etabonate - For safer treatment of GI inflammation. Pharm Res 1992, 9(10, Suppl.): Abst PDD 7327.
9. Li, K., Reidy, J.J., Junega, R., Paulus, P., Stone, T., Thompson, H.W. The effect of intact corneal epithelium on the comparative antiinflammatory efficacy of topical opthalmic corticosteroids. Invest Ophthalmol Visual Sci 1996, 37(3): Abst 4718.
10. Bodor, N., Varga, M. Effect of a novel steroid on the wound healing of rabbit cornea. Exp Eye Res 1990, 50: 183-7.
11. Druzgala, P., Wu, W.-M., Bodor, N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991, 10: 933-7.
12. Hochhaus, G., Chen, L.-S., Ratka, A., Druzgala, P., Howes, J., Bodor, N., Derendorf, H. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992, 81: 1210-5.
13. Loftsson, T., Bodor, N. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Adv Drug Deliv Rev 1994, 14: 293-9.
14. Wu, W.-M., Bodor, N. Metabolism and excretion of loteprednol etabonate, a soft corticosteroid, in rats. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8128.
15. Bodor, N., Wu., W.-M., Murakami, T., Engel, S. Soft drugs 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995, 12: 875-9.
16. Bodor, N., Loftsson, T., Wu, W.-M. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992, 9: 1275-9.
17. Reddy, I.K., Khan, M.A., Wu, W.-M., Bodor, N.S. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocular Pharmacol Ther 1996, 12: 159-67.
18. Keates, E.U., Druzgala, P.D., Howes, J.F., Reaves, T.A. Loteprednol etabonate: A new steroid without ocular hypertensive effect. Invest Ophthalmol Visual Sci 1991, 32(4): Abst 1372.
19. Zbyszynski, B., Abelson, M., Howes, J. A randomized, double-masked, placebo controlled paired comparison of loteprednol etabonate 0.5% ophthalmic suspension (LE) bid or qid versus placebo in an antigen challenge model of acute allergic conjunctivitis. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2012.
20. George, M., Abelson, M., Howes, J. A randomized, double-masked, placebo controlled paired comparison of loteprednol etabonate 0.1%, 0.2% or 0.3% ophthalmic suspension (LE) versus placebo in an antigen challenge model of acute allergic conjunctivitis. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2019.
21. Howes, J., Strahlman, E. A randomized, double-masked, placebo controlled, parallel group study of the effects of loteprednol etabonate 0.2% ophthalmic suspension (LE) in patients with seasonal allergic conjunctivitis. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2020.
22. Strahlman, E., Howes, J. A randomized, double-masked, placebo controlled, parallel group study of the effects of loteprednol etabonate 0.2% opthalmic suspension (LE) in patients with seasonal allergic conjunctivitis. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 1025.
23. Dell, S.J., Shulman, D.G., Lowry, G.M. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate (LE) in the treatment of seasonal allergic conjunctivitis (SAC). Invest Ophthalmol Visual Sci 1995, 36(4): Abst 3949.
24. Dell, S.J., Shulman, D.G., Lowry, G.M., Howes, J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Amer J Ophthalmol 1997, 123: 791-7.
25. Laibovitz, R.A., Ghormley, N.B., Insler, M.S., Cartee, L., Reaves, T.A. Treatment of giant papillary conjunctivitis with loteprednol etabonate, a novel corticosteroid. Invest Ophthalmol Visual Sci 1991, 32(4): Abst 344.
26. Bartlett, J.D., Howes, J.F., Ghormley, N.R., Amos, J.F., Laibovitz, R., Horwitz, B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993, 12: 313-21.
27. Friedlaender, M.H. and The Loteprednol Etabonate GPC Study Group. Evaluation of loteprednol etabonate in giant papillary conjunctivitis. Invest Ophthalmol Visual Sci 1995, 36(4): Abst 188.
28. Friedlaender, M.H., Howes, J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Amer J Ophthalmol 1997, 123: 455-64.
29. Howes, J.F., Asbell, P.A. A double-masked placebo-controlled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of contact-lens associated giant papillary conjunctivitis. Invest Ophthalmol Visual Sci 1995, 36(4): Abst 2891.
30. Bartlett, J.D., Horwitz, B., Laibovitz, R., Howes, J.F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocular Pharmacol 1993, 9: 157-65.
31. Neumann, R., Howes, J.F. Loteprednol etabonate: A novel ocular steroid with improved safety profile. In: Advances in Ocular Immunology, R.B. Nussenblatt, S.M. Whitcup, R.R. Caspi and I. Gery (Eds.), Elsevier Sciences B.V., 1994, 245-8.
32. Lotemax deemed approvable by FDA. Prous Science Daily Essentials September 26, 1997.
33. Pharmos, Bausch & Lomb expand Lotemax agreement. Prous Science Daily Essentials May 17, 1996.
34. Novack, G.D., Howes, J. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite PJ-91 following chronic ocular administration. Clin Pharmacol Ther 1996, 59(2): Abst PIII-59.
35. 1-cortienic acid, the metabolites of a soft corticosteroid, loteprednol etabonate. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8127.
36. Sloan, K.B., Perrin, J.H. Comments concerning "pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs". J Pharm Sci 1994, 83: 1066.
37. Rachwal, S., Pop, E., Brewster, M.E. Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques. Steroids 1996, 61: 524-30.
38. Rachwal, S., Druzgala, P., Liu, Z.-Z., Brewster, M.E., Pop, E. Synthesis and structural studies by NMR of some steroids related to loteprednol etabonate. 213th ACS Natl Meet (April 13-17, San Francisco) 1997, Abst ORGN 501.